Design of PLGA based nanoparticles for imaging guided applications

Area of Science:

• Nanotechnology
• Medical Imaging
• Materials Science

Background:

• Gadolinium (Gd(III)) complexes are essential for magnetic resonance imaging (MRI) contrast agents.
• Developing stable and sensitive contrast agents for targeted drug delivery remains a challenge.
• Polylactic-co-glycolic acid (PLGA) nanoparticles offer a versatile platform for drug and contrast agent delivery.

Purpose of the Study:

• To develop a novel, highly sensitive MRI contrast agent using Gd(III)-loaded PLGA nanoparticles.
• To evaluate the stability, relaxivity, and in vivo performance of these Gd(III)-loaded PLGA nanoparticles.
• To explore the potential of these nanoparticles as theranostic agents for imaging-guided drug delivery.

Main Methods:

• Efficient loading of an amphiphilic Gd(III) complex into PLGA nanoparticles via oil/water emulsions.
• Characterization of nanoparticle stability in buffer and particle size using dynamic light scattering.
• Measurement of millimolar relaxivity of the incorporated Gd(III) complex at 21.5 MHz.
• In vivo imaging of nanoparticle accumulation in murine melanoma xenografts using MRI.

Main Results:

• PLGA nanoparticles successfully encapsulated the Gd(III) complex, exhibiting stability for over a week without agent release.
• The Gd(III)-loaded PLGA nanoparticles demonstrated a millimolar relaxivity of 21.7 mM(-1) s(-1), approximately 5 times higher than commercial agents.
• Relaxometric efficiency was inversely proportional to nanoparticle size.
• In vivo MRI confirmed accumulation of the PLGA nanoparticles in murine melanoma xenografts.

Conclusions:

• Gd(III)-loaded PLGA nanoparticles represent a novel, highly sensitive MRI contrast agent.
• The nanoparticles exhibit excellent stability and enhanced relaxivity, suitable for advanced imaging applications.
• These theranostic agents hold significant potential for imaging-guided drug delivery and cancer therapy.